ENvue Medical Delisted from Nasdaq, Shifts to OTC Trading
Event summary
- Nasdaq Hearings Panel denied ENvue Medical’s request for continued listing, effective September 16, 2026.
- Trading of ENvue’s common stock will shift to OTC Markets under the same symbol, ‘FEED’.
- The decision does not impact ENvue’s business operations, products, or commercial activities.
- ENvue is evaluating all available procedures, including a further appeal under Nasdaq Listing Rules.
The big picture
ENvue Medical’s delisting from Nasdaq highlights the challenges faced by smaller medical technology companies in maintaining exchange compliance. The shift to OTC trading could limit access to institutional investors and increase volatility, while the company’s focus on commercializing its navigation and therapeutic ultrasound platforms remains critical for long-term growth. The decision underscores the importance of regulatory adherence in the medical device sector, where operational continuity and market access are key to sustaining investor trust.
What we're watching
- Regulatory Appeal
- Whether ENvue’s potential appeal to Nasdaq will succeed or lead to further delays in regaining exchange listing.
- Market Impact
- How the shift to OTC trading will affect liquidity and investor confidence in ENvue’s stock.
- Commercial Strategy
- The pace at which ENvue can advance the commercialization of its ENvue Navigation System and other technologies amid the delisting.
Related topics